Hormone Treatments May Raise Blood Pressure in Transgender People
MONDAY, April 19, 2021 -- Monitoring blood pressure is important for transgender people, according to new research, which found changes in systolic blood pressure after the start of gender-affirming hormone therapy.
Transgender men and transgender... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 19, 2021 Category: General Medicine Source Type: news
Gender-affirming hormone therapy may increase risk of high blood pressure
(Beth Israel Deaconess Medical Center) In the largest and longest observational study of its kind, physician-researchers from Beth Israel Deaconess Medical Center (BIDMC) found that gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2021 Category: International Medicine & Public Health Source Type: news
This Femtech Company Is Pioneering Mucus Engineering As A New Alternative To Hormonal Birth Control
Cirqle Biomedical is a startup pioneering mucus engineering as a new alternative to hormonal birth control, based in Copenhagen, and its team recently demonstrated the first novel and effective approach to contraception since hormonal therapy was introduced more than 60 years ago. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 14, 2021 Category: Pharmaceuticals Authors: Marija Butkovic, Contributor Tags: ForbesWomen /forbeswomen Leadership /leadership Innovation /innovation Healthcare /healthcare Source Type: news
Benefits and Risks of Menopausal HT Among Women 50-59 Benefits and Risks of Menopausal HT Among Women 50-59
This report analyzes additional years of follow-up from the Women ' s Health Initiative hormone therapy trials, with a focus on participants 50-59 years of age. Does the new data change recommendations?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2021 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
CTC mutations may predict outcomes in some castrate-resistant prostate cancer patients
(American Association for Cancer Research) Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 26, 2021 Category: Cancer & Oncology Source Type: news
Hormone Therapy May Reduce Nocturia After Menopause
TUESDAY, March 23, 2021 -- The percentage of postmenopausal women experiencing nocturia two or more times per night was lower among those who selected systemic hormone treatment compared with no treatment, according to a study published online March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2021 Category: Pharmaceuticals Source Type: news
Prostate cancer uses metabolic switch to thrive after hormone therapy
(Duke University Medical Center) Studying the cellular metabolism of prostate cancer, a team of Duke Health-led researchers identified a key reason hormone therapies eventually fail, while also laying out a way to bypass the problem using an entirely new therapeutic approach. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 22, 2021 Category: Cancer & Oncology Source Type: news
Hormone therapy shown to reduce effects of nocturia in postmenopausal women
(The North American Menopause Society (NAMS)) CLEVELAND, Ohio (March 17, 2021)--As women age, they are more likely to wake up in the middle of the night to pass urine. The loss of estrogen during the menopause transition accelerates this problem, which is known as nocturia. A new study evaluated the effectiveness of different hormone therapies in managing the frequency of nocturia. Study results are published online today inMenopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 17, 2021 Category: International Medicine & Public Health Source Type: news
Hormone Therapy and Sexual Function During Menopausal Transition Hormone Therapy and Sexual Function During Menopausal Transition
Does hormonal therapy have a positive impact on sexual function in perimenopausal women?Menopause (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news
ACOG Advises on Care for Transgender Patients ACOG Advises on Care for Transgender Patients
The committee opinion provides guidance for ob-gyns. on topics including inclusivity, routine screening, fertility and reproductive issues, hormone therapy, medication use, and surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
Molecular imaging determines effectiveness of novel metastatic breast cancer treatment
(Society of Nuclear Medicine and Molecular Imaging) Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news
Genomic test helps estimate risk of prostate cancer metastasis, death
(Johns Hopkins Medicine) A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2021 Category: Cancer & Oncology Source Type: news
Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposiu...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Imaging identifies breast cancer patients unlikely to benefit from hormone therapy
(Washington University School of Medicine) Hormone therapy can be very effective for so-called estrogen receptor-positive breast cancer. But it only works for a little more than half of women who receive the treatment. In a small study, researchers at Washington University School of Medicine in St. Louis found that women whose tumors did not respond to a one-day estrogen challenge did not benefit from hormone therapy. The findings could help doctors choose treatments most likely to help their patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2021 Category: International Medicine & Public Health Source Type: news
